Trial Profile
A prospective, non-interventional, multicenter, observational study evaluating post authorization safety of Clottafact in patients with congenital afibrinogenemia in real-life clinical practice in France
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2017
Price :
$35
*
At a glance
- Drugs Fibrinogen (Primary)
- Indications Afibrinogenaemia
- Focus Adverse reactions
- 08 Mar 2017 New trial record